lx101
Gene therapyexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jul 2, 2022 (NCT06196827)
Timeline
Indications
Mechanism of action
- Retinoid isomerohydrolaseSupplementation
RPE65 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07054632 | Phase 3 | Sep 13, 2023 | Innostellar Biotherapeutics |
| NCT06212297 | Phase 1/Phase 2 (Phase 2) | Sep 12, 2023 | Innostellar Biotherapeutics |
| NCT06024057 | N/A | Sep 1, 2023 | Jiao Tong University |
| NCT06196827 | Phase 1/Phase 2 (Phase 2) | Jul 2, 2022 | Innostellar Biotherapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innostellar Biotherapeutics | For profit | 3 | 3 | 2 | 2022 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1